Why This Regimen is Highly Unusual and Likely Not Evidence-Based
This combination of 150 mg daily intramuscular progesterone plus 25-43 mg DHEA is not supported by current guidelines or high-quality evidence for perimenopausal symptom management, and the progesterone dose/route is particularly concerning as it far exceeds standard recommendations.
Critical Issues with This Regimen
Progesterone Dosing and Route Problems
The 150 mg daily IM progesterone injection is not a standard perimenopausal treatment. According to FDA labeling, IM progesterone is indicated for amenorrhea and abnormal uterine bleeding due to hormonal imbalance, not routine perimenopausal symptom management 1.
For perimenopausal symptoms, the evidence-based approach is oral micronized progesterone (OMP4) 300 mg at bedtime, not daily IM injections 2, 3. This oral formulation:
- Treats vasomotor symptoms effectively (55% reduction in hot flushes/night sweats)
- Improves sleep quality
- Can be given cyclically (days 14-27) in menstruating perimenopausal women
- Addresses the underlying physiology where estradiol levels are actually 26% higher than normal while progesterone becomes insufficient 2
The IM route at 150 mg daily represents an unusual and potentially excessive approach that increases risks of adverse effects including breakthrough bleeding, edema, weight changes, breast tenderness, and thromboembolic events 1.
DHEA Supplementation Concerns
The evidence for DHEA at 25-43 mg in perimenopausal women is weak to negative. The 2014 Endocrine Society guideline on androgen therapy found that the most rigorous study (50 mg/day DHEA for 1 year) showed no benefit on cognitive performance, and a Cochrane Review concluded there was no evidence that DHEA improves cognitive performance in people over 50 without dementia 4.
A 2015 Cochrane systematic review of 28 trials with 1,273 menopausal women found:
- DHEA did not improve quality of life compared to placebo (moderate quality evidence)
- DHEA was associated with androgenic side effects, mainly acne (OR 3.77) 5
- A 1999 RCT specifically in symptomatic perimenopausal women showed DHEA supplementation "does not improve perimenopausal symptoms or well-being compared to placebo" 6
What This Regimen Might Indicate
This unusual combination could suggest:
Off-label/alternative medicine approach: Not following evidence-based guidelines from major endocrine societies 7
Possible fertility treatment context: High-dose progesterone is sometimes used in assisted reproduction, though this would be unusual in a 45-year-old perimenopausal woman
Misunderstanding of perimenopausal physiology: The common misconception that estrogen is "low" in perimenopause, when actually estradiol levels are elevated and erratic while progesterone becomes deficient 2
Evidence-Based Alternative Approach
For a symptomatic 45-year-old perimenopausal woman, the appropriate treatment would be:
Oral micronized progesterone 300 mg at bedtime (cyclically on days 14-27 if still menstruating, or daily if in late perimenopause) for vasomotor symptoms, sleep disturbances, and breast tenderness 2, 3
DHEA supplementation is NOT recommended for general perimenopausal symptoms based on current evidence 5, 6
DHEA may have limited utility only in specific contexts: adrenal insufficiency, women on chronic glucocorticoids, or documented sexual dysfunction with low libido 8
Common Pitfalls to Avoid
- Do not use IM progesterone for routine perimenopausal symptom management - the oral route is preferred and evidence-based
- Do not assume estrogen deficiency in perimenopause - estradiol is typically elevated and erratic, not low
- Do not prescribe DHEA for general "anti-aging" or well-being - this is not supported by high-quality evidence
- Ensure proper endometrial protection if any estrogen therapy is used - progesterone must be given at least 12 days per month in women with a uterus 7
The described regimen warrants careful review and likely modification to align with evidence-based guidelines for perimenopausal symptom management.